Vít Procházka

Vít Procházka

Auto-generated profile, based on publicly available information

Vít Procházka

Department of Haemato-Oncology, Faculty of Medicine and Dentistry, Palacky University and University Hospital, Olomouc, Czech Republic

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 August 2012 in New England Journal of Medicine
Verified
Journal Article
Open access
PDF file
HKH.C. Kluin-Nelemans
H.C. Kluin-Nelemans
EHE. Hoster
E. Hoster
OHOlivier Hermine
Olivier Hermine
JWJan Walewski
Jan Walewski
MTMarek Trněnỳ
Marek Trněnỳ
MDM.H. Dreyling
M.H. Dreyling
The long-term prognosis for older patients with mantle-cell lymphoma is poor. Chemoimmunotherapy results in low rates of complete remission, and most patients have a relapse. We investigated whether a fludarabine-containing induction regimen improved the complete-remission rate and whether maintenance therapy with rituximab prolonged remission. We randomly assigned patients 60 years of age or older with mantle-cell lymphoma, stage II to IV, who were not eligible for high-dose therapy to six cycles of rituximab, fludarabine, and cyclophosphamide (R-FC) every 28 days or to eight cycles of rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) every 21 days. Patients who had a response underwent a second randomization to maintenance therapy with rituximab or interferon alfa, each given until progression. Of the 560 patients enrolled, 532 were included in the intention-to-treat analysis for response, and 485 in the primary analysis for response. The median age was 70 years. Although complete-remission rates were similar with R-FC and R-CHOP (40% and 34%, respectively; P=0.10), progressive disease was more frequent with R-FC (14%, vs. 5% with R-CHOP). Overall survival was significantly shorter with R-FC than with R-CHOP (4-year survival rate, 47% vs. 62%; P=0.005), and more patients in the R-FC group died during the first remission (10% vs. 4%). Hematologic toxic effects occurred more frequently in the R-FC group than in the R-CHOP group, but the frequency of grade 3 or 4 infections was balanced (17% and 14%, respectively). In 274 of the 316 patients who were randomly assigned to maintenance therapy, rituximab reduced the risk of progression or death by 45% (in remission after 4 years, 58%, vs. 29% with interferon alfa; hazard ratio for progression or death, 0.55; 95% confidence interval, 0.36 to 0.87; P=0.01). Among patients who had a response to R-CHOP, maintenance therapy with rituximab significantly improved overall survival (4-year survival rate, 87%, vs. 63% with interferon alfa; P=0.005). R-CHOP induction followed by maintenance therapy with rituximab is effective for older patients with mantle-cell lymphoma. (Funded by the European Commission and others; ClinicalTrials.gov number, NCT00209209.)

14 June 2013 in Leukemia & Lymphoma
Verified
Journal Article
Closed access
PDF file
TPTomáš Papajík
Tomáš Papajík
MMMiroslav Mysliveček
Miroslav Mysliveček
RURenata Urbanová
Renata Urbanová
EBEva Buriánková
Eva Buriánková
ZKZuzana Kapitáňová
Zuzana Kapitáňová
KIKarel Indrák
Karel Indrák
The significance of positron emission tomography/computed tomography (PET/CT) in chronic lymphocytic leukemia (CLL) has not yet been systematically studied. This prospective study was aimed at assessing the benefit of PET/CT in patients with newly diagnosed or relapsed CLL and Richter transformation (RT). PET/CT examination was performed in 23 patients with newly diagnosed disease, 13 with relapsed disease and eight with suspected or histopathologically confirmed RT. In all patients, the maximum standardized uptake value (SUVmax) was calculated. The median SUVmax was 3.4 (range: 1.5–6.3) and 3.1 (range: 1.2–5.9) in newly diagnosed and relapsed patients, respectively. The median SUVmax of patients with suspected or confirmed RT reached 16.5 (range: 7.2–25.3), a value different from that of the previous groups (p < 0.001). 2-[18F]fluoro- 2-deoxy-d-glucose (18F-FDG) PET/CT revealed inflammatory lesions in seven patients (16%) and synchronous tumors in two newly diagnosed patients.18F-FDG PET/CT may be a beneficial imaging method when used in individuals with CLL and suspected RT.

8 August 2017 in Oncotarget
Verified
Journal Article
Open access
PDF file
GMGayane Manukyan
Gayane Manukyan
TPTomas Papajik
Tomas Papajik
PGPetr Gajdos
Petr Gajdos
ZMZuzana Mikulkova
Zuzana Mikulkova
RURenata Urbanova
Renata Urbanova
EKEva Kriegova
Eva Kriegova
A growing body of studies highlights involvement of neutrophils in cancer development and progression. Our aim was to assess the phenotypic and functional properties of circulating neutrophils from patients with chronic lymphocytic leukemia (CLL). The percentage of CD54+ and CD64+ neutrophils as well as CD54 expression on these cells were higher in CLL patients than in age-matched healthy controls. Neutrophils from CLL produced more reactive oxygen species (ROS) compared to controls in both resting and activated conditions. Lipopolysaccharide-induced production of IL-1β and TNF-a as well as reduced TLR2 expression in neutrophils from CLL than in neutrophils from controls suggesting their tolerant state. Finally, phenotypic alterations of neutrophils, particularly elevation of CD64 and CD54 markers, correlated with disease activity and treatment, and low percentage of neutrophils. Taken together, the alterations in percentage and functional characteristics of neutrophils reflect the clinical course of CLL. Our data provide first evidence that neutrophils in CLL are permanently primed and have functional defects.

1 November 2018 in Clinical Lymphoma Myeloma and Leukemia
Verified
Journal Article
Closed access
AOAleš Obr
Aleš Obr
VPVít Procházka
Vít Procházka
AJAndrea Jirkuvová
Andrea Jirkuvová
HUHelena Urbánková
Helena Urbánková
EKEva Kriegova
Eva Kriegova
TPTomáš Papajík
Tomáš Papajík

18 April 2016 in Leukemia & Lymphoma
Verified
Journal Article
Closed access
PDF file
HMHeidi Mocikova
Heidi Mocikova
RPRobert Pytlik
Robert Pytlik
ASAlice Sykorova
Alice Sykorova
AJAndrea Janikova
Andrea Janikova
VPVit Prochazka
Vit Prochazka
OGon behalf of Czech Lymphoma Study Group
on behalf of Czech Lymphoma Study Group
We have investigated whether the addition of rituximab to methotrexate, procarbazine, vincristine, radiotherapy and cytarabine was associated with improved outcome of primary central nervous system lymphomas (PCNSL). Of 164 patients, 49 received rituximab. Median age was 63 years, median Karnofsky performance score (KPS) was 60 and median follow-up of living patients was 59.5 months. 1- and 2-year PFS were 49.7 and 37.9%, 1- and 2-year OS were 57.0 and 45.3%. Median progression-free survival (PFS), but not overall survival (OS) was significantly better for patients treated with rituximab (22.9 vs. 10.9 months, p = 0.037). In multivariate analysis, age ≤70 years and KPS ≥90 were predictive for PFS and OS, rituximab was an independent prognostic factor for PFS only. In landmark analyses, rituximab was not found beneficial for long-term survivors and no group particularly benefited from rituximab. In conclusion, addition of rituximab was associated with improved PFS, but not OS in this unselected cohort of PCNSL patients.

1 July 2011 in Clinical Nuclear Medicine
Verified
Journal Article
Closed access
TPTomáš Papajík
Tomáš Papajík
MMMiroslav Mysliveček
Miroslav Mysliveček
ZŠZuzana Šedová
Zuzana Šedová
EBEva Buriánková
Eva Buriánková
VPVít Procházka
Vít Procházka
KIKarel Indrák
Karel Indrák
Cases of synchronous non-Hodgkin lymphoma (NHL) and second primary carcinoma in previously untreated immunocompetent patients are relatively rare. The aim of this part of our prospective study was to a revealed 2-F-18 fluoro-2-deoxy-D-glucose (F-18 FDG) positron emission tomography (PET)-positive lesion in an extranodal organ suggestive of second primary neoplasm in newly diagnosed NHL patients. A total of 209 patients with NHL underwent initial staging F-18 FDG PET/computed tomography (CT). The finding was assessed by a radiologist, nuclear medicine physician, and hematologist. In 6 suspicious cases (2.9%) of second neoplasm, the decision was made to perform further investigations before lymphoma therapy. Two patients were diagnosed with colorectal carcinoma, 1 with esophageal adenocarcinoma, 1 with invasive ductal breast carcinoma, 1 with medullary thyroid carcinoma, and 1 with squamous cell lung carcinoma. In 5 of the 6 patients, the second solid tumor was completely asymptomatic and revealed only by F-18 FDG PET/CT examination. We conclude that in patients with NHL, appropriate imaging, clinical, and histologic analysis of organ lesions detected by F-18 FDG PET/CT will occasionally demonstrate significant synchronous neoplasms.